首页> 外文OA文献 >Phase III, double-blind, randomized trial that compared maintenance lapatinib versus placebo after first-line chemotherapy in patients with human epidermal growth factor receptor 1/2-positive metastatic bladder cancer

【2h】

Phase III, double-blind, randomized trial that compared maintenance lapatinib versus placebo after first-line chemotherapy in patients with human epidermal growth factor receptor 1/2-positive metastatic bladder cancer

机译：III期，双盲，随机试验，比较维持拉帕替尼与安慰剂后一线化疗对人表皮生长因子受体1/2阳性转移性膀胱癌患者的影响

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Powles, Thomas; Huddart, Robert A.; Elliott, Tony; Sarker, Shah-Jalal; Ackerman, Charlotte; Jones, Robert; Hussain, Syed; Crabb, Simon; Jagdev, Satinder; Chester, John; Hilman, Serena; Beresford, Mark; Macdonald, Graham; Santhanam, Sundar; Frew, John A.; Stockdale, Andrew; Hughes, Simon; Berney, Daniel; Chowdhury, Simon;
展开▼
作者单位

展开▼
年度 2017
总页数
原文格式 PDF
正文语种 en
中图分类

相似文献

外文文献
中文文献
专利

1. Reply to Pontus Eriksson, Gottfrid Sj?dahl, and Fredrik Liedberg's Letter to the Editor re: Thomas Powles, Robert A. Huddart, Tony Elliott, et al. Phase III, Double-blind, Randomized Trial that Compared Maintenance Lapatinib versus Placebo after First-line Chemotherapy in Patients with Human Epidermal Growth Factor Receptor 1/2-positive Metastatic Bladder Cancer. J Clin Oncol 2017;35:48–55. Knowing HER2 Status is Not Enough: A Molecular Subtype Approach to Bladder Cancer is Also Needed [J] . Thomas Powles, Alfonso Gómez de Lia?o, Charlotte Ackerman European urology . 2017,第5期

机译：回复Pontus Eriksson，Gottfrid SJ？Dahl，以及Fredrik Liedberg的信Re：Thomas Powers，Robert A. Huddart，Tony Elliott等。 III期，双盲，随机试验，将Lapatinib与安慰剂进行比较患者人体表皮生长因子受体1/2阳性转移性膀胱癌的一线化疗后的安慰剂。 J Clin Oncol 2017; 35：48-55。知道HER2状态是不够的：还需要一种分子亚型对膀胱癌的方法
2. Re: Phase III, Double-Blind, Randomized Trial that Compared Maintenance Lapatinib versus Placebo after First-Line Chemotherapy in Patients with Human Epidermal Growth Factor Receptor 1/2-Positive Metastatic Bladder Cancer Editorial Comment [J] . Chang Sam S. The Journal of Urology . 2018,第4期

机译：Re：III期，双盲，随机试验，在人表皮生长因子受体1/2阳性转移性膀胱癌患者中比较了Lapatinib对安慰剂的维护rapatinib与安慰剂编辑评论
3. Re: Phase III, Double-Blind, Randomized Trial that Compared Maintenance Lapatinib versus Placebo after First-Line Chemotherapy in Patients with Human Epidermal Growth Factor Receptor 1/2-Positive Metastatic Bladder Cancer Editorial Comment [J] . Chang Sam S. The Journal of Urology . 2018,第4期

机译：Re：III期，双盲，随机试验，在人表皮生长因子受体1/2阳性转移性膀胱癌患者中比较了Lapatinib对安慰剂的维护rapatinib与安慰剂编辑评论
4. HER1 THERAPEUTIC CANCER VACCINE: AN ACTIVE IMMUNOTHERAPY TREATMENT FOR PATIENTS WITH TUMORS EXPRESSING THE RECEPTOR OF EPIDERMAL GROWTH FACTOR (EGF-R) [C] . Eduardo Suarez, Belinda Sanchez, Zaima Mazorra, Conference on vaccine technology VI . 2018

机译：HER1癌症治疗疫苗：一种针对表皮生长因子（EGF-R）受体的肿瘤的主动免疫疗法
5. A Phase II, Randomized, Double-Blind, Placebo-Controlled Trial of Fish Oil (Eicosapentaenoic Acid and Docosahexaenoic Acid) on Lung and Systemic Inflammation in Patients with Acute Lung Injury. [D] . Stapleton, Renee Doney. 2010

机译：鱼油（二十碳五烯酸和二十二碳六烯酸）对急性肺损伤患者的肺和全身炎症的II期，随机，双盲，安慰剂对照试验。
6. Estrogen Receptor Progesterone Receptor Human Epidermal Growth Factor Receptor 2 (HER2) and Epidermal Growth Factor Receptor Expression and Benefit From Lapatinib in a Randomized Trial of Paclitaxel With Lapatinib or Placebo As First-Line Treatment in HER2-Negative or Unknown Metastatic Breast Cancer [O] . Richard S. Finn, Michael F. Press, Judy Dering, -1

机译：紫杉醇与拉帕替尼或安慰剂作为HER2阴性或未知转移性乳腺癌的一线治疗的随机试验雌激素受体孕激素受体人表皮生长因子受体2（HER2）和表皮生长因子受体的表达及拉帕替尼的获益
7. Phase III, Double-Blind, Randomized Trial That Compared Maintenance Lapatinib Versus Placebo After First-Line Chemotherapy in Patients With Human Epidermal Growth Factor Receptor 1/2-Positive Metastatic Bladder Cancer [O] . Powles, Thomas, Huddart, Robert A, Elliott, Tony, 2017

机译：III期双盲，随机试验，比较了人表皮生长因子受体1/2阳性转移性膀胱癌患者在一线化疗后维持拉帕替尼与安慰剂的疗效

Phase III, double-blind, randomized trial that compared maintenance lapatinib versus placebo after first-line chemotherapy in patients with human epidermal growth factor receptor 1/2-positive metastatic bladder cancer

著录项

引文网络

相似文献

相关主题

期刊订阅